JP7611045B2 - プロテアーゼ阻害剤、その調製、および使用 - Google Patents

プロテアーゼ阻害剤、その調製、および使用 Download PDF

Info

Publication number
JP7611045B2
JP7611045B2 JP2021055886A JP2021055886A JP7611045B2 JP 7611045 B2 JP7611045 B2 JP 7611045B2 JP 2021055886 A JP2021055886 A JP 2021055886A JP 2021055886 A JP2021055886 A JP 2021055886A JP 7611045 B2 JP7611045 B2 JP 7611045B2
Authority
JP
Japan
Prior art keywords
alkyl
compound
occurrence
tautomer
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021055886A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022108241A5 (https=
JP2022108241A (ja
Inventor
洪 涛 于
奇 胡
晶 黄
廷 亮 王
寧 可 侯
莉 ▲ジン▼ 張
文 芸 張
巧 珠 譚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Westlake Pharmaceutical Hangzhou Co Ltd
Original Assignee
Westlake Pharmaceutical Hangzhou Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Westlake Pharmaceutical Hangzhou Co Ltd filed Critical Westlake Pharmaceutical Hangzhou Co Ltd
Publication of JP2022108241A publication Critical patent/JP2022108241A/ja
Publication of JP2022108241A5 publication Critical patent/JP2022108241A5/ja
Application granted granted Critical
Publication of JP7611045B2 publication Critical patent/JP7611045B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2021055886A 2021-01-12 2021-03-29 プロテアーゼ阻害剤、その調製、および使用 Active JP7611045B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNPCT/CN2021/071256 2021-01-12
PCT/CN2021/071256 WO2022150962A1 (en) 2021-01-12 2021-01-12 Protease inhibitors, preparation, and uses thereof

Publications (3)

Publication Number Publication Date
JP2022108241A JP2022108241A (ja) 2022-07-25
JP2022108241A5 JP2022108241A5 (https=) 2022-09-20
JP7611045B2 true JP7611045B2 (ja) 2025-01-09

Family

ID=75277880

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021055886A Active JP7611045B2 (ja) 2021-01-12 2021-03-29 プロテアーゼ阻害剤、その調製、および使用

Country Status (5)

Country Link
US (1) US11958830B2 (https=)
EP (1) EP4026830A1 (https=)
JP (1) JP7611045B2 (https=)
CN (2) CN113072497B (https=)
WO (1) WO2022150962A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3089678A1 (en) 2018-01-31 2019-08-08 Heparegenix Gmbh Protein kinase mkk4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
WO2019243315A1 (en) 2018-06-21 2019-12-26 Heparegenix Gmbh Tricyclic protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
US11912701B2 (en) 2018-07-16 2024-02-27 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
AU2021207236A1 (en) 2020-01-15 2022-08-11 Heparegenix Gmbh 3-benzoyl-1h-pyrrolo[2,3-b]pyridine derivatives as MKK4 inhibitors for treating liver diseases
JP2024178473A (ja) * 2021-09-03 2024-12-25 塩野義製薬株式会社 ウイルス増殖阻害活性を有する二環性含窒素複素環誘導体およびそれらを含有する医薬組成物
US20250042889A1 (en) 2021-09-07 2025-02-06 Shanghai Qilu Pharmaceutical Research And Development Centre Ltd. 3clpro protease inhibitor
TW202408511A (zh) 2022-08-05 2024-03-01 美商基利科學股份有限公司 Ｓａｒｓ－ｃｏｖ２主蛋白酶抑制劑
US20240158368A1 (en) 2022-10-14 2024-05-16 Abbvie Inc. Pyrrolidine Main Protease Inhibitors as Antiviral Agents
WO2024124287A1 (en) * 2022-12-12 2024-06-20 The Walter And Eliza Hall Institute Of Medical Research Compounds for treating viral infection
WO2024183629A1 (zh) * 2023-03-03 2024-09-12 齐鲁动物保健品有限公司 3CLpro蛋白酶抑制剂在制备治疗猫冠状病毒疾病药物中的用途
EP4695230A1 (en) * 2023-04-11 2026-02-18 Westlake Pharmaceuticals (Hangzhou) Co., Ltd. Protease inhibitors and uses thereof
EP4722196A1 (en) 2023-05-31 2026-04-08 Westlake Pharmaceuticals (Hangzhou) Co., Ltd. Crystal of viral protease inhibitor and use

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002531545A (ja) 1998-12-09 2002-09-24 ワイス ヘルペスウイルスのチオ尿素インヒビター
JP2005526100A (ja) 2002-03-19 2005-09-02 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー 殺菌・殺カビ剤として使用するための二環式縮合ピリジニルアミドおよびその有利な組成物
JP2006517563A (ja) 2003-02-14 2006-07-27 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 置換ｎ−アリール複素環化合物、その製造方法およびその医薬としての使用
JP2006528218A (ja) 2003-05-19 2006-12-14 エフ．ホフマン−ラ　ロシュ　アーゲー Ｇｆａｔインヒビター
WO2011151423A1 (en) 2010-06-04 2011-12-08 Exonhit S.A. Substituted isoquinolines and their use as tubulin polymerization inhibitors
WO2014025651A1 (en) 2012-08-06 2014-02-13 Amgen Inc. Chroman derivatives as trpm8 inhibitors
WO2015034271A1 (en) 2013-09-04 2015-03-12 Daewoong Pharmaceutical Co., Ltd. Novel antifungal pyridinylhydrazide derivatives
JP2015509921A (ja) 2012-01-30 2015-04-02 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト イソキノリンおよびナフチリジン誘導体
JP2015514680A (ja) 2012-04-25 2015-05-21 ラクオリア創薬株式会社 Ｔｔｘ−ｓ遮断薬としてのアミド誘導体
WO2016036638A1 (en) 2014-09-05 2016-03-10 Merck Sharp & Dohme Corp. Isoquinoline derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2
WO2017053604A1 (en) 2015-09-23 2017-03-30 The Regents Of The University Of California Potent antiviral pyrazolopyridine compounds
CN107674029A (zh) 2016-08-02 2018-02-09 上海迪诺医药科技有限公司 多环化合物、其药物组合物及应用
WO2018175537A1 (en) 2017-03-22 2018-09-27 Dana-Farber Cancer Institute, Inc. Selective inhibition of gluconeogenic activity
WO2020023813A1 (en) 2018-07-27 2020-01-30 Cocrystal Pharma, Inc. Pyrrolo[2,3-b]pyridin derivatives as inhibitors of influenza virus replication
WO2020065613A1 (en) 2018-09-28 2020-04-02 Janssen Pharmaceutica Nv Monoacylglycerol lipase modulators

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK175069B1 (da) * 1986-03-11 2004-05-24 Hoffmann La Roche Pyrocatecholderivater
US6335350B1 (en) * 1998-12-09 2002-01-01 American Home Products Corporation Acetamide and substituted acetamide-containing thiourea inhibitors of herpes viruses
EP1137633A2 (en) * 1998-12-09 2001-10-04 American Home Products Corporation Acetamide and substituted acetamide-containing thiourea inhibitors of herpes viruses
US7495011B2 (en) * 2003-07-15 2009-02-24 Arigen Pharmaceuticals, Inc. Anti-coronavirus drug
US7732446B1 (en) * 2004-03-11 2010-06-08 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
CA2597446A1 (en) * 2005-02-11 2006-08-31 Coley Pharmaceutical Group, Inc. Substituted imidazoquinolines and imidazonaphthyridines
EP2124568A1 (en) * 2007-01-17 2009-12-02 Merck & Co., Inc. Decahydroquinoline analogs as cb2 receptor modulators
CN101519372B (zh) * 2009-04-01 2011-07-20 深圳市盛捷生物技术有限公司 用作GSK3抑制剂的苯并[e]异吲哚-1,3-二酮化合物及其制备
WO2012090177A2 (en) * 2010-12-30 2012-07-05 Lupin Limited Cannabinoid receptor modulators
EP2780013A4 (en) 2011-11-18 2015-07-01 Constellation Pharmaceuticals Inc MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF
EP2780014A4 (en) 2011-11-18 2015-07-01 Constellation Pharmaceuticals Inc MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF
WO2013078320A1 (en) 2011-11-21 2013-05-30 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
NZ628762A (en) 2012-02-10 2016-07-29 Constellation Pharmaceuticals Inc Modulators of methyl modifying enzymes, compositions and uses thereof
SI2953941T1 (sl) 2013-02-11 2017-08-31 Constellation Pharmaceuticals, Inc. Modulatorji metil-modificirajočih encimov, sestavki in uporabe le-teh
WO2014151142A1 (en) 2013-03-15 2014-09-25 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
EP3033334A1 (en) 2013-08-15 2016-06-22 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
KR101715090B1 (ko) * 2013-08-28 2017-03-13 한국화학연구원 신규한 화합물 또는 이의 약학적으로 허용가능한 염, 및 이를 유효성분으로 함유하는 인플루엔자 바이러스 감염으로 인한 질환의 예방 또는 치료용 약학적 조성물
KR102764027B1 (ko) * 2015-10-15 2025-02-07 코넬 유니버시티 프로테아좀 억제제 및 이의 용도
WO2018002848A1 (en) * 2016-06-30 2018-01-04 VIIV Healthcare UK (No.5) Limited Azadecalin derivatives as inhibitors of human immunodeficiency virus replication
EP3982954A4 (en) * 2019-06-14 2024-01-03 The Trustees of Columbia University in the City of New York NT5C2 INHIBITORS FOR THE TREATMENT OF CHEMOTHERAPY-RESISTANT ACUTE LYMPHOBLASTIC LEUKEMIA

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002531545A (ja) 1998-12-09 2002-09-24 ワイス ヘルペスウイルスのチオ尿素インヒビター
JP2005526100A (ja) 2002-03-19 2005-09-02 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー 殺菌・殺カビ剤として使用するための二環式縮合ピリジニルアミドおよびその有利な組成物
JP2006517563A (ja) 2003-02-14 2006-07-27 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 置換ｎ−アリール複素環化合物、その製造方法およびその医薬としての使用
JP2006528218A (ja) 2003-05-19 2006-12-14 エフ．ホフマン−ラ　ロシュ　アーゲー Ｇｆａｔインヒビター
WO2011151423A1 (en) 2010-06-04 2011-12-08 Exonhit S.A. Substituted isoquinolines and their use as tubulin polymerization inhibitors
JP2015509921A (ja) 2012-01-30 2015-04-02 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト イソキノリンおよびナフチリジン誘導体
JP2015514680A (ja) 2012-04-25 2015-05-21 ラクオリア創薬株式会社 Ｔｔｘ−ｓ遮断薬としてのアミド誘導体
WO2014025651A1 (en) 2012-08-06 2014-02-13 Amgen Inc. Chroman derivatives as trpm8 inhibitors
WO2015034271A1 (en) 2013-09-04 2015-03-12 Daewoong Pharmaceutical Co., Ltd. Novel antifungal pyridinylhydrazide derivatives
WO2016036638A1 (en) 2014-09-05 2016-03-10 Merck Sharp & Dohme Corp. Isoquinoline derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2
WO2017053604A1 (en) 2015-09-23 2017-03-30 The Regents Of The University Of California Potent antiviral pyrazolopyridine compounds
CN107674029A (zh) 2016-08-02 2018-02-09 上海迪诺医药科技有限公司 多环化合物、其药物组合物及应用
WO2018175537A1 (en) 2017-03-22 2018-09-27 Dana-Farber Cancer Institute, Inc. Selective inhibition of gluconeogenic activity
WO2020023813A1 (en) 2018-07-27 2020-01-30 Cocrystal Pharma, Inc. Pyrrolo[2,3-b]pyridin derivatives as inhibitors of influenza virus replication
WO2020065613A1 (en) 2018-09-28 2020-04-02 Janssen Pharmaceutica Nv Monoacylglycerol lipase modulators

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Bioorganic & Medicinal Chemistry，2011年，19 (2)，pp.939-950
Organic Letters，2002年，4 (2)，pp.193-196

Also Published As

Publication number Publication date
CN116751164B (zh) 2026-03-13
JP2022108241A (ja) 2022-07-25
CN113072497B (zh) 2023-04-14
US11958830B2 (en) 2024-04-16
WO2022150962A1 (en) 2022-07-21
US20220227731A1 (en) 2022-07-21
CN113072497A (zh) 2021-07-06
CN116751164A (zh) 2023-09-15
EP4026830A1 (en) 2022-07-13

Similar Documents

Publication Publication Date Title
JP7611045B2 (ja) プロテアーゼ阻害剤、その調製、および使用
EP3056493B1 (en) Substituted pyrrolidines as factor xia inhibitors for the treatment of thromboembolic diseases
EP2794616B1 (en) Pyrimidin-4-one derivatives and their use in the treatment, amelioration or prevention of a viral disease
AU2012358332A1 (en) Hepatitis B antiviral agents
TW202345801A (zh) 具有病毒增殖抑制活性之尿嘧啶衍生物及含有其等之醫藥組合物
CN102526087B (zh) 核苷类化合物在制备治疗肠病毒71(ev71)感染疾病药物的应用
CN115160301B (zh) 一种山荷叶素衍生物、其制备方法及用途
JP2018501268A (ja) チゾキサニドホスフェート及びアルカンスルホネート並びにその医薬用途
JPH07500604A (ja) 高血圧治療用エチルアラニンアミノジオール化合物
JP2008516901A (ja) 非ペプチドブラジキニンアンタゴニストおよびそれによる医薬組成物
CN104478830B (zh) 一组叔胺类拟肽衍生物及其在抑制hiv-1蛋白酶中的应用
CA3178647A1 (en) Substituted tricyclic amides, analogues thereof, and methods using same
HK40077416A (en) Protease inhibitors, preparation, and uses thereof
HK40050067B (en) Protease inhibitors, preparation, and uses thereof
HK40050067A (en) Protease inhibitors, preparation, and uses thereof
WO2021214073A1 (en) Antiviral 1,3-di-oxo-indene compounds
WO2024212101A1 (en) Protease inhibitors and uses thereof
JPS5934175B2 (ja) Ｎ，ｎ−ジ置換アミノメチルフェニルエタノ−ルアミン類
WO2023213728A1 (en) Substituted aryl esters of coumarin-3-carboxylic acid and their use as host cell proteases inhibitors
KR20260014614A (ko) P2x3 억제제의 제조 방법 및 중간체
WO2022156693A1 (zh) 含有n-(取代磺酰基)乙酰胺结构的病毒蛋白酶抑制剂，及其在抗病毒药物中的应用
CA3254824A1 (en) Inhibitors of Molluscum contagiosum infection and methods of using them
WO2017206688A1 (zh) 一种取代的吡咯烷化合物及药物组合物及其应用
CN102206177A (zh) 1-萘基苯甲酮衍生物及其制备方法和用途
CN104447390A (zh) 取代环丁烷类神经氨酸酶抑制剂及其使用方法和用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210428

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20220525

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220525

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220909

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220909

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230817

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230905

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231204

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240305

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240605

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240903

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241105

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241203

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241223

R150 Certificate of patent or registration of utility model

Ref document number: 7611045

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150